WuXi XDC Cayman Inc. (2268.HK)
Manufactures specialized drug components and cancer medications for pharmaceutical companies worldwide
53.00-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-4.5%
The outlook
WuXi XDC trades at 53, sitting well below both its 50- and 200-day moving averages and near the lower end of its 52-week range. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and the average price target implies significant upside from current levels. The stock carries a trailing P/E of 40.8, reflecting elevated valuation despite its depressed technical position.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 20 analysts
Price trendBelow its 50- & 200-day averages
52-week range23% of the way from its 52-week low to high
Price targetAvg target +56% vs current price
Analyst price target
~12-month · 20 analysts82.68average target+56.0% vs now
Now 53.00
Low 70.44High 107.67
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$67.12B
52-wk high
85.50
52-wk low
43.50
50-day avg
54.29
200-day avg
61.62
Trailing P/E
40.8